Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anabolic therapy for osteoporosis.

John P Bilezikian1

  • 1Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.

International Journal of Fertility and Women'S Medicine
|December 13, 2005
PubMed
Summary

Newer osteoporosis drugs like teriparatide offer anabolic benefits, restoring bone microarchitecture. This contrasts with antiresorptive agents, which halt bone deterioration, providing new treatment options beyond calcium and vitamin D.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bacterial specificity of the gut microbiome predicts bone density in primary hyperparathyroidism.

Bone research·2026
Same author

Clinical profile, treatment practices, and complications in chronic hypoparathyroidism in a Middle Eastern cohort.

Journal of the Endocrine Society·2026
Same author

Journal of Bone and Mineral Research (JBMR) 40th anniversary celebration the third decade (part 1).

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Vitamin D in Gut and Systemic Immune Tolerance and in Infections' Risk: An International Evidence-Based Consensus Statement.

Reviews in endocrine & metabolic disorders·2026
Same author

Treatment of hypoparathyroidism (HypoPT): Position Statement of the Expert Group for Polish Society of Endocrinology - update 2026.

Endokrynologia Polska·2026
Same author

Journal of Bone and Mineral Research (JBMR) 40th anniversary celebration: the beginning and first decade.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Area of Science:

  • Endocrinology
  • Bone Biology
  • Pharmacology

Background:

  • Osteoporosis treatment historically relied on calcium, vitamin D, and hormone replacement therapy.
  • Hormone replacement therapy is no longer a primary osteoporosis treatment due to risks.
  • Antiresorptive agents (bisphosphonates, raloxifene, calcitonin) are current mainstays, preventing fractures by reducing bone turnover.

Purpose of the Study:

  • To describe the activities of bisphosphonates and teriparatide.
  • To review studies on the use of bisphosphonates and teriparatide alone and in combination.
  • To highlight teriparatide's anabolic effects on bone microarchitecture.

Main Methods:

  • Review of current literature on bisphosphonates and teriparatide.
  • Analysis of studies investigating monotherapy and combination therapy.
  • Description of the pharmacological actions and clinical effects of these agents.

Main Results:

  • Bisphosphonates and other antiresorptive agents reduce bone turnover and prevent fractures but do not restore bone microarchitecture.
  • Teriparatide, a parathyroid hormone fragment (PTH(1-34)), is anabolic, improving bone microarchitecture by increasing cortical thickness and connectivity.
  • Combination therapy studies are reviewed, exploring synergistic effects.

Conclusions:

  • Teriparatide represents a novel anabolic approach to osteoporosis, restoring bone structure.
  • Bisphosphonates are effective antiresorptive agents, halting disease progression.
  • The combination of anabolic and antiresorptive therapies warrants further investigation for optimal osteoporosis management.

Related Experiment Videos